Skip to content
New: Explore the psychedelic pipeline via our Q3'25 🎯 Bullseye Charts.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh

Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran Singh

  • Post published:April 12, 2024
  • Post category:Interviews/Pα+
Read more about the article Senator Kirk Cullimore on Utah’s MDMA and Psilocybin Pilot Program

Senator Kirk Cullimore on Utah’s MDMA and Psilocybin Pilot Program

  • Post published:April 3, 2024
  • Post category:Interviews
Read more about the article Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field

Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field

  • Post published:March 19, 2024
  • Post category:Interviews/Pα+
Read more about the article Bay Staters for Natural Medicine Co-Founder, James Davis, on Grassroots Psychedelic Policy Reform, a Community-based Facilitator Network, and the Corporatisation of Psychedelics

Bay Staters for Natural Medicine Co-Founder, James Davis, on Grassroots Psychedelic Policy Reform, a Community-based Facilitator Network, and the Corporatisation of Psychedelics

  • Post published:March 8, 2024
  • Post category:Interviews
Read more about the article A Discussion with Ernesto Londoño, Author of “Trippy: The Peril and Promise of Medicinal Psychedelics”

A Discussion with Ernesto Londoño, Author of “Trippy: The Peril and Promise of Medicinal Psychedelics”

  • Post published:February 1, 2024
  • Post category:Interviews
Read more about the article Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and Competitive Landscape

Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and Competitive Landscape

  • Post published:January 31, 2024
  • Post category:Interviews/Pα+
Read more about the article Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the Non-Medical Use of Psychedelics

Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the Non-Medical Use of Psychedelics

  • Post published:November 20, 2023
  • Post category:Interviews/Pα+
Read more about the article Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic Research

Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic Research

  • Post published:November 20, 2023
  • Post category:Interviews/Pα+

End of content

No more pages to load

← Newer Posts

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More